

CITATION REPORT

List of articles citing

Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial

DOI: 10.1001/jama.295.13.joc60038

JAMA - Journal of the American Medical Association, 2006, 295, 1519-30.

Source: <https://exaly.com/paper-pdf/41106315/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
771	ST-Elevation Acute Myocardial Infarction. 19-49		
770	Antiplatelet therapy versus other antithrombotic strategies. 2001 , 367-385		
769	Retention of atherogenic lipoproteins in atherogenesis. 2004 , 61, 4-9		18
768	Proteins interacting with the 26S proteasome. 2004 , 61, 1589-95		32
767	Coping with new challenges in acute coronary syndromes. <i>Canadian Journal of Cardiology</i> , 2006 , 22 Suppl C, 13C-20C	3.8	
766	Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. 2006 , 15, 843-55		77
765	Myocardial ischemia and infarction. <i>Journal of the American College of Cardiology</i> , 2006 , 47, D13-7	15.1	11
764	Update and rationale for ongoing acute myocardial infarction trials: combination therapy, facilitation, and myocardial preservation. 2006 , 151, S30-9		10
763	[Targets of antithrombotic drugs]. 2006 , 22, 887-94		1
762	OASIS-5: how do fondaparinux and enoxaparin compare in patients with acute coronary syndromes?. 2006 , 3, 474-5		2
761	Clinical efficacy and safety of fondaparinux: an emphasis on results in the elderly. 2006 , 2, 731-743		
760	Bibliography. Current world literature. Imaging and echocardiography. 2006 , 21, 529-35		
759	Independent design and conduct of clinical trials. 2006 , 3, 503-7		3
758	Clinical trials update from the annual scientific session of the American College of Cardiology 2006. 2006 , 98, 36Q-41Q		1
757	New anticoagulants. 2006 , 2006, 450-6		43
756	Can fondaparinux safely prevent the occurrence of venous thromboembolism in acutely ill medical patients?. 2006 , 3, 358-9		0
755	[Cardiology -- an update]. 2006 , 131, 1435-7		

754	The scientific community's quest to identify optimal targets for anticoagulant pharmacotherapy. <i>Circulation</i> , 2006 , 114, 2313-6	16.7	11
753	Fondaparinux in ST-segment elevation myocardial infarction: the drug, the strategy, the environment, or all of the above?. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 295, 1579-80	27.4	8
752	Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. <i>European Heart Journal</i> , 2007 , 28, 1193-204	9.5	216
751	Abstracts of the 5th International Meeting on Intensive Cardiac Care, October 14-16, 2007, Tel Aviv, Israel. 2007 , 9, 134-74		
750	ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed	16.7	927
749	Predictive and protective factors associated with upper gastrointestinal bleeding after cardiovascular percutaneous coronary intervention: a case-control study. 2007 , 102, 2411-6		62
748	Elderly patients should not be denied fibrinolytic therapy. 2007 , 4, 520-1		
747	Fondaparinux sodium in the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism. 2007 , 7, 227-37		1
746	Antagonists of activated factor X and thrombin: innovative antithrombotic agents. 2007 , 5, 121-8		3
745	Infarct-related left ventricular diverticulum. <i>European Heart Journal</i> , 2007 , 28, 1204	9.5	0
744	Pharmacological antithrombotic adjuncts to percutaneous coronary intervention. 2007 , 8, 759-76		1
743	Enoxaparin and ST-elevation myocardial infarction: reply. <i>European Heart Journal</i> , 2007 , 28, 2952-2953	9.5	
742	Antithrombin treatment in patients with non-ST-elevation acute coronary syndromes undergoing percutaneous coronary intervention. 2007 , 9, A11-A24		1
741	Anticoagulant therapy in acute coronary syndromes. 2007 , 3, 301-8		
740	Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction. <i>JAMA - Journal of the American Medical Association</i> , 2007 , 298, 2399-405	27.4	118
739	[Emergency therapy and intensive care of patients with acute coronary syndromes]. 2007 , 132, 1515-24		0
738	ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/NonST-Elevation Myocardial Infarction: Executive Summary. <i>Circulation</i> , 2007 , 116, 803-877	16.7	158
737	Managing acute coronary syndrome: evidence-based approaches. 2007 , 64, S14-24		5

736	Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. <i>Circulation</i> , 2007 , 115, 2570-89	16.7	398
735	Beyond unfractionated heparin and warfarin: current and future advances. <i>Circulation</i> , 2007 , 116, 552-60	16.7	178
734	Women, acute ischemic heart disease, and antithrombotic therapy: challenges and opportunities. <i>Circulation</i> , 2007 , 115, 2796-8	16.7	6
733	Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial. <i>Circulation</i> , 2007 , 115, 2642-51	16.7	80
732	Acute ST-Segment-Elevation Myocardial Infarction. 205-231		
731	Antithrombotic strategies in non-ST elevation acute coronary syndromes: focus on bivalirudin. 2007 , 3, 345-64		6
730	Bibliography. Current world literature. Thoracic anaesthesia. 2007 , 20, 83-6		
729	Differential effects of direct thrombin inhibitors and antithrombin-dependent anticoagulants on the dynamics of clot formation. 2007 , 18, 97-103		22
728	Low molecular weight heparin and bleeding in patients with chronic renal failure. 2007 , 13, 409-13		43
727	Beyond the platelet count: heparin antibodies as independent risk predictors. 2007 , 153, 900-6		30
726	Global outcomes of ST-elevation myocardial infarction: comparisons of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (EXTRACT-TIMI 25) registry and trial. 2007 , 154, 54-61		14
725	Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs. 2007 , 154, 3-11		86
724	Reperfusion strategies in the emergency treatment of ST-segment elevation myocardial infarction. 2007 , 25, 353-66		18
723	A model of heterotopic aortic valve replacement for studying thromboembolism prophylaxis in mechanical valve prostheses. 2007 , 141, 1-6		8
722	Non-ST-elevation acute coronary syndromes. 2007 , 369, 801-803		14
721	The impact of bleeding in patients with acute coronary syndromes: how to optimize the benefits of treatment and minimize the risk. <i>Canadian Journal of Cardiology</i> , 2007 , 23, 663-71	3.8	22
720	Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. <i>European Heart Journal</i> , 2007 , 28, 1598-660	9.5	1438
719	Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. <i>European Heart Journal</i> , 2007 , 28, 2077-86	9.5	143

718	Anticoagulants in heart disease: current status and perspectives. <i>European Heart Journal</i> , 2007 , 28, 880-913	94
717	Perceived disability and lifestyle modification following hospitalization for non-ST elevation versus ST elevation acute coronary syndromes: the patients' point of view. 2007 , 6, 287-92	20
716	Anemia in patients undergoing percutaneous coronary intervention: current issues and future directions. 2007 , 7, 225-33	1
715	New trials and therapies for acute myocardial infarction. 2007 , 91, 729-49; xii	3
714	Anticoagulation in atrial fibrillation: a contemporary viewpoint. 2007 , 4, S34-9	13
713	[Ischemic heart disease: 2006 update]. 2007 , 60 Suppl 1, 3-18	2
712	Guía de Práctica Clínica para el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST. 2007 , 60, 1070.e1-1070.e80	14
711	Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 2238-46	15.1 100
710	ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the <i>Journal of the American College of Cardiology</i> , 2007 , 50, e1-e157	15.1 1412
709	ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/NonST-Elevation Myocardial Infarction Executive Summary. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 652-726	15.1 216
708	Reperfusion strategies in acute ST-segment elevation myocardial infarction: a comprehensive review of contemporary management options. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 917-29	15.1 109
707	Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 1742-51	15.1 203
706	Beyond heparin and warfarin: the new generation of anticoagulants. 2007 , 16, 271-82	57
705	Efficacy and safety of fondaparinux in patients with acute coronary syndromes. 2007 , 5, 1013-26	5
704	New anticoagulants. 2007 , 27, 41-47	14
703	Clot structure modification by fondaparinux and consequence on fibrinolysis: A new mechanism of antithrombotic activity. <i>Thrombosis and Haemostasis</i> , 2007 , 97, 27-31	7 16
702	Guidelines for the management of acute coronary syndromes 2006. 2007 , 186, 101; discussion 101-2	
701	. 2007 ,	1

700	Anti-platelet and anti-thrombotic approaches in patients undergoing percutaneous coronary intervention. 2007 , 70, 388-406	15
699	Pharmacokinetics and pharmacodynamics of the dual FII/FX inhibitor BIBT 986 in endotoxin-induced coagulation. 2007 , 81, 858-66	18
698	Myocardial infarction: contemporary management strategies. 2007 , 262, 59-77	12
697	Combined antiplatelet and anticoagulant therapy: clinical benefits and risks. 2007 , 5 Suppl 1, 255-63	64
696	The challenge of ST-segment elevation myocardial infarction. 2007 , 61, 2079-92	2
695	Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. 2007 , 27, 1558-70	11
694	The Editor's Roundtable: arterial thrombosis and acute coronary syndromes. 2007 , 100, 974-80	2
693	[Contrast media and percutaneous coronary interventions]. 2007 , 56, 2-9	1
692	The use of antithrombotics for acute coronary syndromes in the emergency department: considerations and impact. 2007 , 50, 167-80	0
691	Anticoagulants and their reversal. 2007 , 21, 37-48	160
690	Percutaneous coronary interventions in patients with heparin-induced thrombocytopenia. 2007 , 9, 396-405	3
689	Reperfusion strategies for ST-elevation myocardial infarction. 2007 , 9, 281-8	6
688	New anticoagulant options for ST-elevation myocardial infarction and unstable angina pectoris/non-ST-elevation myocardial infarction. 2007 , 9, 289-97	3
687	Frühe Antiplättchentherapie und Gerinnungshemmung bei akutem Koronarsyndrom. 2007 , 10, 500-510	
686	Advances in antithrombin and antiplatelet therapy for percutaneous coronary intervention. 2007 , 1, 284-289	
685	Low-molecular-weight heparin use in acute coronary syndromes and percutaneous coronary interventions: An update. 2007 , 1, 303-309	
684	Use of anticoagulants in ST-segment elevation myocardial infarction patients; a focus on low-molecular-weight heparin. 2008 , 22, 59-69	2
683	Primary percutaneous coronary intervention for ST-elevation myocardial infarction using an intravenous and subcutaneous enoxaparin low molecular weight heparin regimen. 2008 , 26, 85-90	8

682	[Therapy of acute myocardial infarction in the prehospital setting]. 2008 , 49, 1023-30		
681	[Antithrombotic therapy of acute myocardial infarction]. 2008 , 49, 1031-7		
680	New data on early management of patients with ST-elevation myocardial infarction. 2008 , 10, 291-8		
679	Which heparin and how much?. 2008 , 10, 312-8		1
678	Thrombophies ^ l'h�parine: est-ce la fin?. 2008 , 2008, 12-14		
677	2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2008 , 71, E1-40		23
676	Reperfusion strategies in ST-elevation myocardial infarction--current status and perspectives for early and pre-hospital treatment. 2008 , 77, 296-305		6
675	2007 focused update to the ACC/AHA guidelines for the management of patients with ST-segment elevation myocardial infarction: implications for emergency department practice. 2008 , 52, 344-355.e1		39
674	Detection of surface bound complement at increasing serum anticoagulant concentrations. 2008 , 62, 214-9		
673	Impact of red blood cell transfusion on clinical outcomes in patients with acute myocardial infarction. 2008 , 102, 115-9		81
672	Enoxaparin: a review of its use in ST-segment elevation myocardial infarction. 2008 , 68, 691-710		13
671	Antithrombotic therapies in primary angioplasty: rationale, results and future directions. 2008 , 68, 2325-44		6
670	Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 2008 , 133, 257S-298S		549
669	Spotlight on fondaparinux sodium in acute coronary syndromes. 2008 , 22, 413-5		1
668	2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Journal of the American College of Cardiology</i> , 2008 , 51, 210-47	15.1	648
667	2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. <i>Journal of the American College of Cardiology</i> , 2008 , 51, 172-209	15.1	503
666	Anticoagulants in coronary artery disease. 2008 , 26, 615-28		5
665	Fondaparinux: use in thromboprophylaxis of acute medical patients. 2008 , 25, 81-8		4

664	Predictors of outcome in patients undergoing PCI. Results of the RIVIERA study. 2008 , 129, 379-87		54
663	The medical management of acute coronary syndromes and potential roles for new antithrombotic agents. 2008 , 34, 417-28		3
662	Sustained coronary patency after fibrinolytic therapy as independent predictor of 10-year cardiac survival Observations from the Antithrombotics in the Prevention of Reocclusion in COronary Thrombolysis (APRICOT) trial. 2008 , 155, 1039-46		5
661	Management of ST-segment elevation myocardial infarction in EDs. 2008 , 26, 91-100		9
660	The use of adjunctive anticoagulants in patients with acute coronary syndrome transitioning to percutaneous coronary intervention. 2008 , 26, 932-41		1
659	Excess heparin dosing among fibrinolytic-treated patients with ST-segment elevation myocardial infarction. 2008 , 121, 805-10		11
658	Heparin: from animal organ extract to designer drug. 2008 , 122, 753-62		43
657	Guidelines for anticoagulant use in acute coronary syndromes. 2008 , 371, 1559-61		12
656	Acute myocardial infarction. 2008 , 372, 570-84		466
655	2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf	16.7	520
654	Optimisation de la prise en charge des patients avec un infarctus aigu du myocarde avec l'élevation du segment 'ST': stratégies clés aux urgences et en préhospitalier. 2008 , 21, 138-146		0
653	Cardiologie. 2008 ,		18
652	Heparins, low-molecular-weight heparins, and pentasaccharides: use in the older patient. 2008 , 26, 145-55, v		13
651	Fondaparinux sodium: a review of its use in the management of acute coronary syndromes. 2008 , 8, 113-25		15
650	An examination of effect estimation in factorial and standardly-tailored designs. 2008 , 5, 121-30		12
649	2007 Guideline update for unstable angina/non-ST-segment elevation myocardial infarction: focus on antiplatelet and anticoagulant therapies. 2008 , 42, 989-1001		11
648	The impact of pre-hospital thrombolytic treatment on re-infarction rates: analysis of the Myocardial Infarction National Audit Project (MINAP). 2009 , 95, 559-63		13
647	Angioplasty strategies in ST-segment-elevation myocardial infarction: part I: primary percutaneous coronary intervention. <i>Circulation</i> , 2008 , 118, 538-51	16.7	37

646	Will warfarin soon be pass? New approaches to stroke prevention in atrial fibrillation. <i>Journal of Cardiovascular Pharmacology</i> , 2008 , 52, 18-27	3.1	9
645	Selective factor Xa inhibition with fondaparinux: from concept to clinical benefit. 2008 , 10, C1-C7		6
644	Adjunctive antithrombotic therapy during primary percutaneous coronary intervention. 2008 , 10, J2-J14		
643	Transglutaminase activity in acute infarcts predicts healing outcome and left ventricular remodelling: implications for FXIII therapy and antithrombin use in myocardial infarction. <i>European Heart Journal</i> , 2008 , 29, 445-54	9.5	62
642	The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial. <i>European Heart Journal</i> , 2008 , 29, 324-31	9.5	47
641	Tailored antithrombotic therapy for acute coronary syndromes. 2008 , 6, 935-44		
640	Rivaroxaban: an oral direct inhibitor of factor Xa. 2008 , 65, 1520-9		58
639	Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. <i>European Heart Journal</i> , 2008 , 29, 2909-45	9.5	1774
638	Anticoagulant Agents. 2008 , 195-232		
637	2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group on Revising New Evidence and Updating the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing Group. <i>Circulation</i> , 2008 , 117, 296-329	16.7	858
636	Bias in AJHP supplements. 2008 , 65, 2328-9; author reply 2329-30; discussion 2330		1
635	Catheter-related thrombosis: biological and clinical evidence for risk with currently available anticoagulants. 2009 , 15, 183-96		
634	Clinical Guide to the Use of Antithrombotic Drugs in Coronary Artery Disease. 2008 ,		
633	Insulin therapy in acute coronary syndromes: an appraisal of completed and ongoing randomised trials with important clinical end points. 2008 , 5, 276-84		5
632	Immunogenicity of Biopharmaceuticals. 2008 ,		6
631	Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment. <i>European Heart Journal</i> , 2008 , 29, 315-23	9.5	30
630	Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials. <i>Circulation</i> , 2008 , 118, 2038-46	16.7	76
629	Recent developments in acute coronary syndromes. 2008 , 8, 42-8		0

628	Survival of heparins, oral anticoagulants, and aspirin after the year 2010. 2008 , 34, 58-73		54
627	Continuum of care in the treatment of ST-segment elevation myocardial infarction (STEMI): importance of platelet and coagulation inhibition. 2008 , 120, 67-78		
626	Re-examining aggressive anticoagulant therapy: the case of acute coronary syndromes. 2008 , 5, 72-3		0
625	Antithrombotic therapy to support primary PCI. 2008 , 358, 2280-2		12
624	Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 2008 , 133, 708S-775S		88
623	Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. 2008 , 111, 4871-9		208
622	Skeletal toxicity of thiazolidinediones. 2008 , 148, 563		9
621	Fondaparinux in patients with impaired renal function: the right choice?. 2008 , 148, 561; author reply 561-2		
620	New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 2008 , 133, 234S-256S		186
619	Platelet Physiology and the Role of the Platelet in Ischemic Heart Disease. 1-14		
618	Factor Xa inactivation in acute coronary syndrome. 2008 , 14, 1186-90		7
617	Clinical benefit and practical use of fondaparinux in the invasive management of patients with acute coronary syndromes. 2008 , 10, C14-C21		1
616	Effect of fondaparinux 2.5 mg once daily on mortality: a meta-analysis of phase III randomized trials of venous thromboembolism prevention. 2008 , 10, C8-C13		7
615	Updated Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) ST-segment elevation myocardial infarction critical pathway toolkit. 2008 , 7, 223-31		4
614	Antithrombotic potential of GW813893: a novel, orally active, active-site directed factor Xa inhibitor. <i>Journal of Cardiovascular Pharmacology</i> , 2008 , 52, 66-71	3.1	16
613	In-vitro comparison of fondaparinux, unfractionated heparin, and enoxaparin in preventing cardiac catheter-associated thrombus. 2008 , 19, 279-84		10
612	New anticoagulants. 2008 , 15, 509-15		33
611	Reperfusion strategies in acute ST-segment elevation myocardial infarction. 2008 , 23, 613-9		5

610 Antithrombotische und thrombolytische Therapie beim akuten Koronarsyndrom. **2008**, 28, 438-447

609 ANTITHROMBOTIC THERAPY AT PERCUTANEOUS CORONARY INTERVENTIONS. **2008**, 4, 91-100

1

608 Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudin. *Vascular Health and Risk Management*, **2008**, 4, 493-505

4.4 9

607 Fondaparinux. **2008**, 1-6

606 Acute Coronary Syndromes and Acute Myocardial Infarction. **2008**, 589-646

605 Antitrombóticos nas síndromes coronarianas agudas: diretrizes atuais e novas evidências. **2008**, 20,

604 The importance of efficient depression management in primary care. **2008**, 148, 562; author reply 562-3

603 Guideline adaptation: an appealing alternative to de novo guideline development. **2008**, 148, 563-4; author reply 564-5

7

602 Relevance of recertification for primary care physicians. **2008**, 148, 565; author reply 565-6

601 Gerinnungshemmende Therapie des akuten Koronarsyndroms. **2008**, 28, 62-65

600 Support for National Health Insurance among U.S. Physicians: 5 years later. **2008**, 148, 566-7

8

599 2007 addendum to the National Heart Foundation of Australia/Cardiac Society of Australia and New Zealand Guidelines for the management of acute coronary syndromes 2006. **2008**, 188, 302-3

27

598 New anticoagulant strategies in ST elevation myocardial infarction: trials and clinical implications. *Vascular Health and Risk Management*, **2008**, 4, 305-13

4.4 8

597 The Importance of Efficient Depression Management in Primary Care. **2008**, 148, 562

596 . **2009**,

0

595 CORRESPONDENCE. **2009**, 70, 723-723

594 ANTICOAGULANTS IN ACUTE CORONARY SYNDROME. **2009**, 5, 71-75

593 Treatment of a cohort of patients with acute myocardial infarction and ST-segment elevation. **2009**, 92, 430-6, 448-55, 464-71

5

592 Malignancy-Associated Thrombosis. **2009**, 24, 20-23

591 New anticoagulants - towards the development of an "ideal" anticoagulant. **2009**, 38, 13-29 21

590 Fondaparinux in acute coronary syndromes. **2009**, 5, 1615-23 3

589 Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs. **2009**, 6, 239-51 84

588 Anticoagulation for ST-segment elevation myocardial infarction. *Circulation*, **2009**, 119, 1186-8 16.7 4

587 Acute myocardial infarction associated with ST segment elevation and the new European Society of Cardiology guidelines. **2009**, 95, 1112-7 4

586 Acute coronary syndromes: Diagnosis and management, part II. **2009**, 84, 1021-36 29

585 Leitfaden Herzkatheter. **2009**, 2

584 Clinical pharmacology of antithrombotic drugs in coronary artery disease. **2009**, 3, 465-78 3

583 Differential clinical outcomes associated with hypoglycemia and hyperglycemia in acute myocardial infarction. *Circulation*, **2009**, 120, 2429-37 16.7 99

582 Asistencia prehospitalaria y en el servicio de urgencias. **2009**, 9, 27-33

581 Tratamiento farmacológico en la fase aguda del infarto de miocardio. ¿Qu^o anticoagulante? ¿Qu^o antiagregante? ¿Qu^o otra medicación?. **2009**, 9, 46-53

580 Safety and efficacy of fondaparinux as an adjunctive treatment to thrombolysis in patients with high and intermediate risk pulmonary embolism. **2009**, 28, 320-4 7

579 Catheter thrombosis and percutaneous coronary intervention: fundamental perspectives on blood, artificial surfaces and antithrombotic drugs. **2009**, 28, 366-80 21

578 Optimales pr^ohospitalares Management des ST-Strecken-Hebungsinfarktes. **2009**, 4, 142-149

577 Medical therapy in acute coronary syndromes: which medicines and at what doses?. **2009**, 11, 267-75 2

576 Determining the in-hospital cost of bleeding in patients undergoing percutaneous coronary intervention. **2009**, 22, 266-73 16

575 The many costs of bleeding. **2009**, 22, 274-6

574	The impact of fibrinolytic therapy for ST-segment-elevation acute myocardial infarction. 2009 , 7, 14-20		14
573	Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial. <i>JACC: Cardiovascular Interventions</i> , 2009 , 2, 1083-91	5	34
572	Apixaban metabolism and pharmacokinetics after oral administration to humans. 2009 , 37, 74-81		479
571	Comparative metabolism of ¹⁴ C-labeled apixaban in mice, rats, rabbits, dogs, and humans. 2009 , 37, 1738-48		86
570	Treatment. 2009 , 146-217		
569	A new era for anticoagulants. 2009 , 20, 562-8		39
568	Prolonged anticoagulation therapy adjunctive to aspirin after successful fibrinolysis: from early reduction in reocclusion to improved long-term clinical outcome. 2009 , 157, 532-40		2
567	Glucose levels compared with diabetes history in the risk assessment of patients with acute myocardial infarction. 2009 , 157, 763-70		25
566	Design and rationale of the Evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) trial. 2009 , 158, 726-33		4
565	Management of ST-segment elevation myocardial infarction: Comparison of the updated guidelines from North America and Europe. 2009 , 158, 695-705		12
564	Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: a proposal from the academic bleeding consensus (ABC) multidisciplinary working group. 2009 , 158, 881-886.e1		27
563	Hospitals with and without percutaneous coronary intervention capability: considerations for treating acute coronary syndromes. 2009 , 27, 595-606		1
562	Consensus of the French Society of Gerontology and Geriatrics and the French Society of Cardiology for the management of coronary artery disease in older adults. 2009 , 102, 829-45		13
561	Antithrombotics in acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2009 , 54, 969-84	15.1	44
560	Ticagrelor versus clopidogrel in patients with acute coronary syndromes. 2009 , 361, 1045-57		4753
559	Antithrombotic therapy for the prevention of reinfarction after reperfusion therapy: the price of success. 2009 , 62, 474-8		
558	Streptokinase and enoxaparin as an alternative to fibrin-specific lytic-based regimens: an ExTRACT-TIMI 25 analysis. 2009 , 69, 1433-43		7
557	Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6. 2009 , 7, 241-9		5

556	Drugs affecting blood coagulation, fibrinolysis, and hemostasis. 2009 , 31, 553-571	
555	Fondaparinux: an overview. 2009 , 7, 577-85	11
554	Safety evaluation of enoxaparin in currently approved indications. 2009 , 8, 745-54	6
553	Management of acute coronary syndromes in Mexico: gaps and opportunities to improve outcomes. 2009 , 9, 143-8	4
552	[Not Available]. 2009 , 62, 293.e1-293.e47	5
551	Tratamiento antitrombótico para la prevención del reinfarcto tras la reperfusión: el precio del éxito. 2009 , 62, 474-478	2
550	Acute Coronary Syndromes: Diagnosis and Management, Part II. 2009 , 84, 1021-1036	29
549	Lowering mortality in ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: key prehospital and emergency room treatment strategies. 2009 , 16, 244-55	9
548	Resolving controversies in hip fracture care: the need for large collaborative trials in hip fractures. 2009 , 23, 479-84	44
547	The current role of anticoagulants in cardiovascular medicine. 2009 , 10, 595-604	13
546	New antithrombotic agents in acute coronary syndromes. 2009 , 24, 313-7	
545	Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors. 2009 , 10, 616-23	16
544	ST-Segment-Elevation Myocardial Infarction. 2009 , 79-121	
543	Year 2008 ESC ST-segment elevation myocardial infarction guidelines: implications for the interventional cardiologist—from evidence to recommendations and practice. 2009 , 11, C31-C37	3
542	Acute myocardial infarction: the enduring challenge for cardiac protection and survival. 2009 , 73, 2000-8	53
541	Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment. 2009 , 2009, 43-45	
540	Bleeding management and pharmacological strategy in primary percutaneous coronary intervention. 2009 , 11, C9-C12	1
539	Update on fondaparinux: role in management of thromboembolic and acute coronary events. 2010 , 8, 96-103	5

538	Factor Xa inhibitors in acute coronary syndromes and venous thromboembolism. 2010 , 8, 5-11	4
537	Syndromes coronaires aigus. 2010 , 5, 1-21	
536	Transradial approach in patients with ST-elevation myocardial infarction treated with abciximab results in fewer bleeding complications: data from EUROTRANSFER registry. 2010 , 21, 292-7	30
535	Guideline adherence for antithrombotic therapy in acute coronary syndrome: an overview in Dutch hospitals. 2010 , 18, 291-9	6
534	Primary PCI for acute myocardial infarction in a patient with idiopathic thrombocytopenic purpura. A case report and review of the literature. 2010 , 35, 43-9	19
533	[STEMI guidelines 2008--Do they influence today's myocardial infarction treatment strategies in rural areas?]. 2010 , 160, 54-60	
532	Antithrombotic therapy in patients with coronary artery disease and with type 2 diabetes mellitus. 2010 , 160, 30-8	8
531	Antithrombotics in acute coronary syndromes: updates from the past year. 2010 , 12, 84-99	1
530	Antithrombotische Therapie beim ST-Streckenhebungsinfarkt. 2010 , 4, 107-123	6
529	Pharmaka zur Thrombozyten- und Gerinnungshemmung in der Behandlung des akuten Koronarsyndroms. 2010 , 4, 239-248	0
528	Antiplatelet and anticoagulant therapies in acute coronary syndromes. 2010 , 24, 61-70	7
527	Practical strategies for the management of anticoagulation therapy: unsolved issues in the cardiac catheterization laboratory. 2010 , 24, 161-74	1
526	Update on heparin: what do we need to know?. 2010 , 29, 199-207	46
525	Antithrombotic therapy in acute coronary syndromes: guidelines translated for the clinician. 2010 , 29, 516-28	4
524	Differential inhibitory effect of fondaparinux on the procoagulant potential of intact monocytes and monocyte-derived microparticles. 2010 , 30, 412-8	7
523	Nuevas evidencias y directrices en antiagregaci3n y anticoagulaci3n en s3ndrome coronario agudo e intervencionismo coronario percut3neo. 2010 , 10, 21C-29C	
522	Tratamiento anticoagulante en el s3ndrome coronario agudo. Reflexiones sobre su estado actual. 2010 , 10, 3-11	
521	Management of ST-elevation myocardial infarction. 2010 , 38, 431-437	

520	Percutaneous coronary intervention. 2010 , 38, 438-445		2
519	[Antithrombotic treatments in acute coronary syndromes with persistent ST-segment elevation]. 2010 , 59, 335-43		
518	Part 9: Acute coronary syndromes: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations. 2010 , 81 Suppl 1, e175-212		39
517	Does enoxaparin have enough FINESSE to replace unfractionated heparin in primary percutaneous coronary intervention?. <i>JACC: Cardiovascular Interventions</i> , 2010 , 3, 213-4	5	
516	Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR ACTION Registry--GWTG (National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry--Get With the Guidelines). <i>JACC: Cardiovascular Interventions</i> , 2010 , 3, 1166-77	5	59
515	Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding. 2010 , 8, 641-50		11
514	Treatment Options in Acute Coronary Syndromes: Focus on Fondaparinux Sodium. 2010 , 2, CMT.S2197		
513	THErapy FOR ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION PATIENTS WHO PRESENT LATE OR ARE INELIGIBLE FOR REPERFUSION. 2010 , 6, 888-901		
512	Anticoagulation. 2010 , 443-451		1
511	Reperfusion Therapies for Acute ST Segment Elevation Myocardial Infarction. 2010 , 110-144		
510	Antithrombotic strategies in patients undergoing percutaneous coronary intervention for acute coronary syndrome. 2010 , 4, 203-20		6
509	Anticoagulation after anterior myocardial infarction and the risk of stroke. 2010 , 5, e12150		15
508	Fondaparinux and acute coronary syndromes: update on the OASIS 5-6 studies. <i>Vascular Health and Risk Management</i> , 2010 , 6, 179-87	4.4	15
507	Recurrent Ischemia after Reperfusion Therapy for Acute Myocardial Infarction. 2010 , 203-211		
506	Part 9: Acute coronary syndromes: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. <i>Circulation</i> , 2010 , 122, S422-65	16.7	74
505	Minimizing the risks of anticoagulants and platelet inhibitors. <i>Circulation</i> , 2010 , 121, 1960-70	16.7	26
504	Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2010 , 304, 1339-49	27.4	130
503	Anticoagulation in the management of non-ST-segment elevation acute coronary syndrome. 2010 , 23, 324-34		1

502	Anticoagulant therapy for percutaneous coronary intervention. 2010 , 3, 80-8		63
501	New anticoagulants. <i>Circulation</i> , 2010 , 121, 1523-32	16.7	227
500	Fondaparinux or enoxaparin: a comparative study of postoperative bleeding in coronary artery bypass grafting surgery. 2010 , 44, 100-6		17
499	Oral antiplatelet therapy after acute coronary syndrome and percutaneous coronary intervention: balancing efficacy and bleeding risk. 2010 , 67, S7-17		3
498	Part 10: acute coronary syndromes: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i> , 2010 , 122, S787-817	16.7	191
497	Anticoagulation in the management of ST-segment elevation myocardial infarction. 2010 , 23, 335-43		
496	Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes. <i>European Heart Journal</i> , 2010 , 31, 50-8	9.5	64
495	Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The global registry of acute coronary events. <i>European Heart Journal</i> , 2010 , 31, 667-75	9.5	53
494	Guidelines on myocardial revascularization. 2010 , 38 Suppl, S1-S52		230
493	Aktuelle Aspekte der modernen interventionellen Koronartherapie. 2010 , 6, 317-334		
492	Blutzuckereinstellung auf Intensivstation Intensiviert oder konservativ?. 2010 , 6, 106-116		
491	Therapy for ST-segment elevation myocardial infarction patients who present late or are ineligible for reperfusion therapy. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 1895-906	15.1	35
490	Clinical pharmacology of direct and indirect factor Xa inhibitors. 2010 , 70, 2153-70		27
489	Examining treatment of ST-elevation myocardial infarction: the importance of early intervention. 2010 , 15, 6-16		9
488	Routine use of fondaparinux in acute coronary syndromes: a 2-year multicenter experience. 2010 , 159, 190-8		14
487	Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial. 2010 , 159, 988-97		22
486	Fondaparinux with Unfractionated heparin during Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): a randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes initially treated with fondaparinux. 2010 , 160, 1029-34, 1034 e1		16
485	Efficacy and safety of fondaparinux in patients with ST-segment elevation myocardial infarction across the age spectrum. Results from the Organization for the Assessment of Strategies for Ischemic Syndromes 6 (OASIS-6) trial. 2010 , 160, 1049-55		9

484	The thrombin hypothesis in ACS: a disappointing disconnect between bench data and bedside clinical trials. 2010 , 123, 103-10		4
483	[A new deal with new anticoagulants?]. 2010 , 35, 146-54		2
482	Guidelines on myocardial revascularization. <i>European Heart Journal</i> , 2010 , 31, 2501-55	9.5	2070
481	Fondaparinux: does it cause HIT? Can it treat HIT?. 2010 , 3, 567-81		65
480	Prise en charge pharmacologique (antiagręants, anticoagulants) du syndrome coronarien aigu. 2010 , 19, 95-102		
479	Adjunctive Pharmacologic Therapies in Acute Myocardial Infarction. 2010 , 145-182		1
478	Use of recombinant factor VIIa (NovoSeven(®)) in 8 patients with ongoing life-threatening bleeding treated with fondaparinux. 2011 , 13, 93-8		22
477	Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo. 2011 , 118, 6667-74		71
476	Recomendaęes sobre revascularizaęo do miocęrdio. 2011 , 30, 951-1005		
475	2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2011 , 58, e11-122	15.1	338
474	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. <i>Journal of the American College of Cardiology</i> , 2011 , 58, 2550-2583	15.1	99
473	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. <i>Journal of the American College of Cardiology</i> , 2011 , 58, e11-122	15.1	1703
472	Factor Xa inhibitors for acute coronary syndromes. 2011 , CD007038		6
471	Pre-hospital treatment of STEMI patients. A scientific statement of the Working Group Acute Cardiac Care of the European Society of Cardiology. 2011 , 13, 56-67		36
470	Comprehensive Cardiovascular Medicine in the Primary Care Setting. 2011 ,		
469	Syndromes coronariens aigus : prise en charge thęrapeutique en urgence. 2011 , 1		1
468	Assessment and management of acute coronary syndromes (ACS): a Canadian perspective on current guideline-recommended treatment--part 2: ST-segment elevation myocardial infarction. <i>Canadian Journal of Cardiology</i> , 2011 , 27 Suppl A, S402-12	3.8	31
467	ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2011 , 32, 2899-3054	9.5	2614

466	Factor Xa and thrombin as targets for new oral anticoagulants. 2011 , 127 Suppl 2, S5-S12		57
465	Antithrombotic therapy in ST-segment elevation myocardial infarction. 2011 , 12, 213-23		2
464	The quest for new anticoagulants: from clinical development to clinical practice. 2011 , 29, e12-22		8
463	Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. 2011 , 378, 693-703		217
462	Antithrombin alternatives in STEMI. 2011 , 378, 643-5		5
461	Implications of bleeding in acute coronary syndrome and percutaneous coronary intervention. <i>Vascular Health and Risk Management</i> , 2011 , 7, 551-67	4.4	12
460	Pharmacologie et Thérapeutique Vasculaire. 2011 , 687-843		
459	Emerging therapies for acute coronary syndromes. 2011 , 2, 61		2
458	Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. <i>Thrombosis and Haemostasis</i> , 2011 , 106, 997-1011	7	184
457	Cardiac protection and pharmacologic management of myocardial ischemia. 1091-1105		
456	Adjunctive pharmacologic therapy in percutaneous coronary intervention: part II anticoagulant therapy. 2011 , 22, 113-21		
455	Emergency cardiac surgery in patients with acute coronary syndromes: a review of the evidence and perioperative implications of medical and mechanical therapeutics. 2011 , 112, 777-99		15
454	Synergy between pharmacological and mechanical reperfusion in ST-segment elevation myocardial infarction patients: 2011 update. 2011 , 12, 860-7		
453	Effects of fondaparinux and a direct factor Xa inhibitor TAK-442 on platelet-associated prothrombinase in the balloon-injured artery of rats. <i>Journal of Cardiovascular Pharmacology</i> , 2011 , 57, 201-6	3.1	4
452	Bleeding avoidance strategies among patients undergoing percutaneous coronary intervention. 2011 , 3, 13-16		
451	Inhibitors of propagation of coagulation: factors V and X. 2011 , 72, 563-80		13
450	Bioavailability of fondaparinux to critically ill patients. 2011 , 26, 342-6		9
449	Anticoagulant agents in acute coronary syndromes. 2011 , 36, 127-68		4

448	2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. 2013 , 82, E266-355		81
447	The role of insulin therapy and glucose normalisation in patients with acute coronary syndrome. 2011 , 19, 79-84		6
446	Age related issues in reperfusion of myocardial infarction. 2011 , 25, 139-48		10
445	Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, Sã Paulo, Brazil. 2011 , 32, 242-66		2
444	Randomized trial of fondaparinux versus heparin to prevent graft failure after coronary artery bypass grafting: the Fonda CABG study. 2011 , 32, 378-85		10
443	[Therapy strategies for acute coronary syndrome and after coronary interventions. Antiplatelet agents and anticoagulants]. 2011 , 52, 1292-300		
442	Einsatz von neuen Antikoagulanzen bei kardiovaskulären Erkrankungen. 2011 , 5, 129-144		
441	Effectiveness and safety of combined antiplatelet and anticoagulant therapy: a critical review of the evidence from randomized controlled trials. 2011 , 25, 123-9		31
440	Future anticoagulants in interventional cardiology: anti-IXa and anti-Xa agents in percutaneous coronary intervention. 2011 , 7, 281-5		
439	Detection of a left atrial thrombus under fondaparinux treatment: a case report. 2011 , 6, 201-3		0
438	The new oral anticoagulants. 2011 , 11, 467-9		3
437	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. <i>Circulation</i> , 2011 , 124, 2574-308	16.7	389
436	Anticoagulant Therapy in Acute Coronary Syndromes with Focus on Fondaparinux. 2011 ,		
435	New anticoagulant agents in acute coronary syndromes. 2011 , 97, 244-52		13
434	Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. <i>European Heart Journal</i> , 2011 , 32, 1854-64	9.5	273
433	2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i> , 2011 , 123, e426-579	16.7	365
432	Is there a role for fondaparinux in perioperative bridging?. 2011 , 68, 36-42		5
431	Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises. 2011 , 16, 203-33		1

430	Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. 2011 , 13, 723-46		166
429	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. <i>Circulation</i> , 2011 , 124, e574-651	16.7	1039
428	Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism. <i>European Heart Journal</i> , 2011 , 32, 1968-76, 1976a	9.5	42
427	Trans-radial approach for catheterisation in non-ST segment elevation acute coronary syndrome: an analysis of major bleeding complications in the ABOARD Study. 2011 , 97, 887-91		15
426	The Interface between Inflammation and Coagulation in Cardiovascular Disease. 2012 , 2012, 860301		27
425	Acute coronary syndrome and cardiogenic shock: management in the cardiac catheterization laboratory. 2012 , 50, 83-113		1
424	The diagnosis and treatment of pulmonary embolism: a metaphor for medicine in the evidence-based medicine era. 2012 , 172, 955-8		24
423	Emerging anticoagulants. 2012 , 19, 3388-416		8
422	Prävention, Diagnostik und Therapie des Akuten Koronarsyndroms [Kooperationen und Netzwerke zur gezielten Therapieeinleitung. 2012 , 41, 514-521		
421	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2012 , 33, 2569-619	9.5	3978
420	Pentacaccharide Derivatives. 2012 , 128-149		
419	Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. 2012 , 344, e553		124
418	Appropriate anti-thrombotic/anti-thrombin therapy for thrombotic lesions. 2012 , 8, 181-91		2
417	Antiplatelet and antithrombin strategies in acute coronary syndrome: state-of-the-art review. 2012 , 8, 239-49		9
416	Enoxaparin for anticoagulation in patients undergoing percutaneous coronary intervention. 2012 , 344, e712		
415	Stratégie de prise en charge des syndromes coronariens aigus. 2012 , 7, 1-15		2
414	In-hospital Acquired Anemia in Acute Coronary Syndrome. Predictors, In-hospital Prognosis and One-year Mortality. 2012 , 65, 742-748		
413	Risque résiduel post-SCA et place des thérapies anti-thrombotiques. 2012 , 2012, 16-17		

412	Pharmacokinetic evaluation of argatroban for the treatment of acute coronary syndrome. 2012 , 8, 1483-93	1
411	The Use of Bivalirudin in ST-Segment Elevation Myocardial Infarction: Advantages and Limitations. 2012 , 1, 441-451	
410	Women and the management of acute coronary syndrome. 2012 , 90, 1151-9	13
409	Tratamiento prehospitalario de los pacientes con IAMCEST. Una declaración científica del Working Group Acute Cardiac Care de la European Society of Cardiology. 2012 , 65, 60-70	3
408	Guía de práctica clínica de la ESC para el manejo del síndrome coronario agudo en pacientes sin elevación persistente del segmento ST. 2012 , 65, 173.e1-173.e55	15
407	Fondaparinux - data on efficacy and safety in special situations. 2012 , 129, 407-17	68
406	Oral direct factor Xa inhibitors. 2012 , 111, 1069-78	78
405	Corn trypsin inhibitor coating attenuates the prothrombotic properties of catheters in vitro and in vivo. 2012 , 8, 4092-100	58
404	Oral factor Xa inhibitors for the long-term management of ACS. 2012 , 9, 392-401	5
403	Acute coronary syndromes: considerations for improved acceptance and implementation of management guidelines. 2012 , 10, 489-503	10
402	Acute Coronary Syndromes (ST Elevation and Non-ST Elevation). 2012 , 86-116	
401	Anticoagulant for primary percutaneous coronary intervention - the last dance for unfractionated heparin?. 2012 , 105, 259-61	1
400	Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomized controlled trials. 2012 , 172, 1537-45	52
399	Heparin in the prophylaxis and treatment of venous thromboembolism and other thrombotic diseases. 2012 , 179-209	8
398	In-hospital acquired anemia in acute coronary syndrome. Predictors, in-hospital prognosis and one-year mortality. 2012 , 65, 742-8	21
397	Cost effectiveness of anticoagulation in acute coronary syndromes. 2012 , 30, 303-21	6
396	ST Segment Elevation Acute Myocardial Infarction and Complications of Myocardial Infarction. 2012 , 434-448	1
395	ALTERNATIVE APPROACHES TO THE USE OF TWO COMPONENT ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME: EVIDENCES, RECOMMENDATIONS AND REAL PRACTICE. 2012 , 8, 531-537	

394	The REG1 anticoagulation system: a novel actively controlled factor IX inhibitor using RNA aptamer technology for treatment of acute coronary syndrome. 2012 , 8, 371-82		31
393	Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 2012 , 141, e495S-e530S		687
392	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. 2012 , 79, 453-95		121
391	Antithrombotic therapy in patients with acute coronary syndrome and diabetes mellitus. 2012 , 37, 264-72		0
390	Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 20-21, 2011, Salvador, Bahia, Brazil. 2012 , 34, 143-63		
389	Pre PCI hospital antithrombotic therapy for ST elevation myocardial infarction: striving for consensus. 2012 , 34, 20-30		2
388	Which antithrombin for whom? Identifying the patient population that benefits most from novel antithrombin agents. 2012 , 14, 493-501		1
387	Modern management of acute myocardial infarction. 2012 , 37, 237-310		12
386	Management of acute coronary syndrome: achievements and goals still to pursue. Novel developments in diagnosis and treatment. 2012 , 271, 521-36		16
385	Improving long-term ACS management: is there a role for the new antiplatelets?. 2012 , 25, 425-32		1
384	Bleeding complications in primary percutaneous coronary intervention of ST-elevation myocardial infarction in a radial center. 2012 , 79, 104-12		19
383	Promise of factor Xa inhibition in acute coronary syndromes. 2012 , 14, 40-8		2
382	2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Journal of the American College of Cardiology</i> , 2013 , 61, 485-510	15.1	433
381	New developments in parenteral anticoagulation for arterial and venous thromboembolism. 2013 , 26, 203-13		8
380	What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention?. 2013 , 382, 633-43		15
379	Stroke Prevention in Atrial Fibrillation. 2013 , 1, 98-104		
378	Management of STEMI. 2013 , 1, 29-36		
377	Akute koronare Syndrome. 2013 , 18, 231-240		

376	Role of Parenteral Agents in Percutaneous Coronary Intervention for Stable Patients. 2013 , 2, 537-551		
375	Basics of Antithrombotic Therapy for Cardiovascular Disease: Pharmacologic Targets of Platelet Inhibitors and Anticoagulants. 2013 , 2, 499-513		1
374	Cardiogenic Shock: Background, Shock Trial/Registry, Evolving Data, Changing Survival, Best Medical Therapy. 2013 , 2, 397-406		1
373	Coagulation factors and recurrence of ischemic and bleeding adverse events in patients with acute coronary syndromes. 2013 , 132, 151-7		18
372	Antiplatelet and Anticoagulation Therapy. 2013 ,		
371	Gender differences in cardiovascular therapy: focus on antithrombotic therapy and percutaneous coronary intervention. 2013 , 73, 1921-33		15
370	A direct comparison of intravenous enoxaparin with unfractionated heparin in primary percutaneous coronary intervention (from the ATOLL trial). 2013 , 112, 1367-72		40
369	Clinical review: bleeding - a notable complication of treatment in patients with acute coronary syndromes: incidence, predictors, classification, impact on prognosis, and management. 2013 , 17, 239		5
368	Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome initially treated with fondaparinux: results from an international, multicenter, randomized pilot study (SWITCH III). 2013 , 26, 107-13		26
367	2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Journal of the American College of Cardiology</i> , 2013 , 61, e78-e140	15.1	2122
366	Current and Future Options for Anticoagulant Therapy in the Acute Management of ACS. 2013 , 15, 21-32		
365	Tools for Assessment of Cardiovascular Tests and Therapies. 2013 , 1-32		
364	NonST-Segment Elevation Acute Coronary Syndromes. 2013 , 153-177		
363	Current antithrombotic agents for acute coronary syndromes: focus on bleeding risk. 2013 , 163, 5-18		15
362	Balance of Ischemia and Bleeding in Selecting an Antithrombotic Regimen. 2013 , 2, 515-525		
361	2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Journal of the American College of Cardiology</i> , 2012 , 61, e78-177	15.1	328
360	Radial versus femoral access for primary percutaneous interventions in ST-segment elevation myocardial infarction patients: a meta-analysis of randomized controlled trials. <i>JACC: Cardiovascular Interventions</i> , 2013 , 6, 814-23	5	143
359	European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. 2013 , 15, 625-51		622

358	Combination Antithrombotic Management of STEMI with Pharmacoinvasive Strategy, Primary PCI, or Rescue PCI. 2013 , 2, 573-583		
357	Anticoagulation treatment. 2013 , 41, 238-241		0
356	Guía de práctica clínica de la ESC para el manejo del infarto agudo de miocardio en pacientes con elevación del segmento ST. 2013 , 66, 53.e1-53.e46		17
355	Monitoring and Reversal of Anticoagulation and Antiplatelets. 2013 , 2, 643-663		1
354	Antiplatelet and anticoagulant strategies in acute coronary syndrome: where we are in 2013. 2013 , 9, 371-85		
353	Antithrombotic Treatment of Cardiovascular Disease. 2013 , 143-173		
352	Antiplatelet and anticoagulant therapy for atherothrombotic disease: the role of current and emerging agents. 2013 , 13, 233-50		35
351	Acute coronary syndromes: advances in antithrombotics. 2013 , 15, 318		1
350	Akute koronare Syndrome. 2013 , 16, 141-151		
349	Emergency management of ST-elevation myocardial infarction. 2013 , 80-96		
348	Prehospital treatment of ST-segment elevated myocardial infarction patients. 2013 , 9, 229-41		4
347	2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i> , 2013 , 127, e669-688	16.7	193
346	The need for novel anticoagulation therapy in acute coronary syndrome. 2013 , 20, 61-6		2
345	Diagnosis and management of ischemic heart disease. 2013 , 39, 202-13		42
344	ST-Segment Elevation Myocardial Infarction. 2013 , 178-213		1
343	2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i> , 2013 , 127, 529-55	16.7	1686
342	2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i> , 2013 , 127, e362-425	16.7	1252
341	Pharmacologic Options for Treatment of Ischemic Disease. 2013 , 83-130		4

340	Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review. <i>European Heart Journal</i> , 2013 , 34, 894-902d	95	20
339	Fondaparinux. 2013 , 30, 172-173a		
338	Parenteral anticoagulants in heart disease: current status and perspectives (Section II). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. <i>Thrombosis and Haemostasis</i> , 2013 , 109, 769-86	7	31
337	Minimizing complications following stent implantation: outcomes and follow-up. 2013 , 5, 301-317		2
336	Lytic failure in the current pharmacointensive ST-elevated acute myocardial infarction care: insights from a pilot real-world study. 2013 , 14, 35-42		0
335	High platelet reactivity--the challenge of prolonged anticoagulation therapy after ACS. <i>Thrombosis and Haemostasis</i> , 2013 , 109, 799-807	7	5
334	Prognostic value of post-procedural aPTT in patients with ST-elevation myocardial infarction treated with primary PCI. <i>Thrombosis and Haemostasis</i> , 2013 , 109, 961-70	7	11
333	Fondaparinux. 2013 , 44-52		
332	Hemostatic Aspects of Cardiovascular Medicine. 2013 , 342-394		
331	Pharmacotherapy in the cardiac catheterization laboratory: evolution and recent developments. 2014 , 10, 885-900		1
330	Management of acute coronary syndrome in special subgroups: female, older, diabetic and Indigenous patients. 2014 , 201, S91-6		1
329	Only high levels of dabigatran attenuate catheter thrombosis in vitro and in rabbits. <i>Thrombosis and Haemostasis</i> , 2014 , 112, 79-86	7	11
328	Fibrinolytic treatment of ST-elevation myocardial infarction. Update 2014. 2014 , 34, 47-53		4
327	Comparative evaluation of efficacy, safety and haemostatic parameters of enoxaparin and fondaparinux in unstable coronary artery disease. 2014 , 8, 31-4		3
326	PK evaluation of fondaparinux sodium for the treatment of thrombosis. 2014 , 10, 269-77		2
325	Heparin versus placebo for non-ST elevation acute coronary syndromes. 2014 , CD003462		5
324	¿Por qu`debemos estratificar el riesgo hemorrágico junto con el isquémico en el síndrome coronario agudo?. 2014 , 14, 10-17		
323	Role of oral factor Xa inhibitors after acute coronary syndrome. 2014 , 129, 224-32		6

322	Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors. 2014 , 349, g6419		36
321	2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i> , 2014 , 130, e344-426	16.7	754
320	Recent advances in antithrombotic treatment for acute coronary syndromes. 2014 , 7, 507-21		4
319	2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i> , 2014 , 130, 2354-94	16.7	696
318	[Antiplatelet therapy and anticoagulation in acute coronary syndrome: current evidence]. 2014 , 39, 692-701		0
317	Anticoagulation and antiplatelet therapy in acute coronary syndromes. 2014 , 81, 103-14		6
316	Risks and Benefits of Thrombolytic, Antiplatelet, and Anticoagulant Therapies for ST Segment Elevation Myocardial Infarction: Systematic Review. 2014 , 2014, 416253		3
315	Pharmacological effects and clinical applications of ultra low molecular weight heparins. 2014 , 8, 1-10		19
314	Acute Coronary Syndrome. 2014 , 49-66		
313	In vitro comparison of the novel, dual-acting FIIa/FXa-inhibitor EP217609C101, unfractionated heparin, enoxaparin, and fondaparinux in preventing cardiac catheter thrombosis. 2014 , 37, 118-30		5
312	Pharmacological Treatment of Acute Coronary Syndromes. 2014 ,		1
311	Triple antithrombotic therapy in cardiac patients: more questions than answers. <i>European Heart Journal</i> , 2014 , 35, 216-23	9.5	31
310	Prise en charge en 2014 des syndromes coronaires aigus avec sus-décalage du segment ST. 2014 , 23, 176-184		
309	Strategia di gestione delle sindromi coronariche acute. <i>EMC - Urgenze</i> , 2014 , 18, 1-14		0
308	2014 AHA/ACC Guideline for the Management of Patients With NonST-Elevation Acute Coronary Syndromes: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 2645-2687	15.1	132
307	Management of ST-elevation myocardial infarction. 2014 , 42, 512-519		1
306	Evaluaci3n del puntaje de sangrado «RUSADE» como prueba diagn3stica para determinar sangrado mayor en pacientes con s3ndrome coronario agudo sin elevaci3n del ST. 2014 , 21, 13-23		2
305	The history of coronary reperfusion. <i>European Heart Journal</i> , 2014 , 35, 2510-5	9.5	36

304	2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). <i>European Heart Journal</i> , 2014 , 35, 2541-619	9.5	3467
303	Management of Acute Coronary Syndrome. 2014 , 238-266		
302	Lessons from primary PCI practice for the next decade. 2014 , 100, 1667-72		5
301	Incremental value of left ventricular systolic and diastolic function to determine outcome in patients with acute ST-segment elevation myocardial infarction: the echocardiographic substudy of the OASIS-6 trial. 2014 , 31, 569-78		19
300	2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Journal of the American College of Cardiology</i> , 2014 , 64, e139-e228	15.1	1822
299	Recent advances in antithrombotic therapy after acute coronary syndrome. 2014 , 186, 589-96		3
298	Therapy in ST-elevation myocardial infarction: reperfusion strategies, pharmacology and stent selection. 2014 , 16, 302		1
297	Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?. 2014 , 168, 611-21		29
296	Gestione delle sindromi coronariche acute nelle prime 48 ore. 2014 , 19, 1-13		
295	Manejo de los síndromes coronarios agudos en las primeras 48 horas. 2014 , 40, 1-14		
294	Antiplatelet and anticoagulation therapy for acute coronary syndromes. 2014 , 114, 1929-43		58
293	Potential antidotes for reversal of old and new oral anticoagulants. 2014 , 133 Suppl 2, S158-66		35
292	The injured patient in the ICU. 261-276		
291	Acute coronary syndromes. 290-302		
290	Perspectives: Direct and specific inhibition of factor Xa: an emerging therapeutic strategy for atherothrombotic disease. 2014 , 16, A56-A60		9
289	Pharmacological Therapy in the Management of Acute Coronary Syndromes. 2015 , 517-531		
288	Comparative efficacy and safety of anticoagulant strategies for acute coronary syndromes. Comprehensive network meta-analysis of 42 randomised trials involving 117,353 patients. <i>Thrombosis and Haemostasis</i> , 2015 , 114, 933-44	7	9
287	Fondaparinux vs. enoxaparin in patients with non-ST elevation acute coronary syndromes (NSTEMI-ACS) treated with percutaneous coronary intervention and tirofiban: an exploratory study in China. 2015 , 40, 584-589		6

286	Developments and risk analysis in anticoagulation. 2015 , 10, 66-73		1
285	Recent advances in the diagnosis and treatment of acute myocardial infarction. <i>World Journal of Cardiology</i> , 2015 , 7, 243-76	2.1	96
284	Management of adjunctive antithrombotic therapy in STEMI patients treated with fibrinolysis undergoing rescue or delayed PCI. <i>Thrombosis and Haemostasis</i> , 2015 , 114, 945-57	7	1
283	. 2015 ,		4
282	Unfractionated heparin-clopidogrel combination in ST-elevation myocardial infarction not receiving reperfusion therapy. 2015 , 241, 151-6		28
281	Cost Effectiveness of Antiplatelet and Antithrombotic Therapy in the Setting of Acute Coronary Syndrome: Current Perspective and Literature Review. 2015 , 15, 415-27		8
280	Treatment of Acute ST-Elevation Myocardial Infarction. 2015 , 505-532		
279	Pathophysiology and Management of Myocardial Infarction. 2015 , 397-424		
278	Medical Treatment of Unstable Angina and Acute Non-ST-Elevation Myocardial Infarction. 2015 , 461-504		0
277	Risks and benefits of triple oral anti-thrombotic therapies after acute coronary syndromes and percutaneous coronary intervention. 2015 , 38, 481-91		6
276	The GRACE registry: how real-life evidence contributes to acute coronary syndrome guidelines. 2015 , 17, D29-D31		3
275	A 35-year journey to evidence-based medicine: a personal story. <i>European Heart Journal</i> , 2015 , 36, 3460-6.5		2
274	Guía de práctica clínica de la ESC sobre revascularización miocárdica, 2014. 2015 , 68, 144.e1-144.e95		1
273	Management of the patient with an acute coronary syndrome using oral anticoagulation. 2015 , 23, 407-14		3
272	The Ideal Anticoagulation Strategy in ST-Elevation Myocardial Infarction. 2015 , 58, 247-59		7
271	Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2015 , 36, 3238-49	9.5	129
270	Diabetes and Cardiovascular Disease. 2015 ,		
269	Update on the guidelines for the management of ST-elevation myocardial infarction. 2015 , 115, 3A-9A		10

268	Activated clotting time during percutaneous coronary intervention: a test for all seasons or a mind tranquilizer?. 2015 , 8,		2
267	Anticoagulation strategies for primary percutaneous coronary intervention: current controversies and recommendations. 2015 , 8,		3
266	[Acute coronary syndrome]. 2015 , 140, 97-103		0
265	Akute koronare Syndrome. 2015 , 12, 7-16		
264	Thrombolysis in Pulmonary Embolism. 2015 ,		3
263	Therapy for Acute Coronary Syndrome and Unstable Angina. 2015 , 467-493		
262	Cardiac Drug Therapy. <i>Contemporary Cardiology</i> , 2015 ,	0.1	2
261	Impact of fondaparinux versus enoxaparin on in-hospital bleeding and 1-year death in non-ST-segment elevation myocardial infarction. FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) 2010. 2015 , 4, 211-9		4
260	THE USE OF ENOXAPARIN IN ACUTE CORONARY SYNDROME. 2016 , 12, 749-757		
259	Conservative pharmacotherapy vs. staged percutaneous coronary intervention for non-culprit vessels in patients with ST-segment elevation myocardial infarction. 2016 , 12, 4147-4153		0
258	Treatment. 145-216		1
257	Fondaparinux and idraparinux. 2016 , 428-432		
256	New Approaches to the Role of Thrombin in Acute Coronary Syndromes: Quo Vadis Bivalirudin, a Direct Thrombin Inhibitor?. 2016 , 21, 284		2
255	Management of Patients With NSTEMI-ACS: A Comparison of the Recent AHA/ACC and ESC Guidelines. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 313-321	15.1	40
254	Primary and Rescue PCI in Acute Myocardial Infarction and Elements of Myocardial Conditioning. 2016 , 155-162		
253	Basics of Antiplatelet and Anticoagulant Therapy for Cardiovascular Disease. 2016 , 377-388		
252	Balance of Ischemia and Bleeding in Selecting Antithrombotic Regimens. 2016 , 389-396		
251	Parenteral Anticoagulant Agents in PCI. 2016 , 408-414		

250	Role of Parenteral Agents in PCI for Stable Patients. 2016 , 421-431		
249	Monitoring and Reversal of Anticoagulation and Antiplatelet Agents. 2016 , 469-483		
248	Cardiovascular Medicine. 2016 , 282-298		
247	Comparison of central adjudication of outcomes and onsite outcome assessment on treatment effect estimates. 2016 , 3, MR000043	21	
246	Statistical issues in designing and interpreting clinical trials in older adults. 2016 , 107-124	0	
245	Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb/IIIa inhibitor tirofiban. 2016 , 3, 13	2	
244	Periprocedural antithrombotic therapy during various types of percutaneous cardiovascular interventions. 2016 , 2, 131-40	15	
243	Controversies in the Management of ST Elevation Myocardial Infarction: Thrombin Inhibition. 2016 , 5, 497-511		
242	Unfractionated heparin or low-molecular-weight heparin in the elderly. 2016 , 222, 1084-1090	6	
241	Insulin in Acute Coronary Syndrome: a Narrative Review with Contemporary Perspectives. 2016 , 30, 493-504	5	
240	Reperfusion Therapy for Acute Myocardial Infarction. 2016 ,		
239	New Therapeutic Agents in Thrombosis and Thrombolysis. 2016 ,	6	
238	Mechanical Reperfusion for STEMI. 2016 ,		
237	Acute Myocardial Infarction in Women: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2016 , 133, 916-47	16.7	572
236	A Central Role for Monocyte-Platelet Interactions in Heart Failure. 2016 , 21, 245-61	12	
235	Edoxaban, a direct factor Xa inhibitor, suppresses tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro: Comparison with an antithrombin-dependent factor Xa inhibitor, fondaparinux. 2016 , 141, 17-21	11	
234	Antithrombotic Therapy in Percutaneous Coronary Intervention. 2016 , 5, 239-247	1	
233	A review of sex-specific benefits and risks of antithrombotic therapy in acute coronary syndrome. <i>European Heart Journal</i> , 2017 , 38, 165-171	9.5	9

232	Risk of Myocardial Infarction in Patients with Long-Term Non-Vitamin K Antagonist Oral Anticoagulant Treatment. 2016 , 58, 483-94		20
231	Transatlantic Comparison of ST-Segment Elevation Myocardial Infarction Guidelines: Insights From the United States and Europe. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 216-229	15.1	19
230	Non-eligibility for reperfusion therapy in patients presenting with ST-segment elevation myocardial infarction: Contemporary insights from the National Cardiovascular Data Registry (NCDR). 2016 , 172, 1-8		8
229	Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes. <i>European Heart Journal</i> , 2016 , 37, 24-34	9.5	333
228	Pathophysiology of ST-segment elevation myocardial infarction: novel mechanisms and treatments. <i>European Heart Journal</i> , 2016 , 37, 1268-83	9.5	59
227	Antithrombotic therapy before, during and after emergency angioplasty for ST elevation myocardial infarction. 2017 , 6, 173-190		11
226	Is routine post-procedural anticoagulation warranted after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction? Insights from the HORIZONS-AMI trial. 2017 , 6, 650-658		4
225	The epidemic of cardiovascular disease in South Asians: Time for action. 2017 , 185, 150-153		3
224	ST-Segment Elevation Myocardial Infarction. 2017 , 30-64		
223	Antithrombotic therapy for patients with STEMI undergoing primary PCI. 2017 , 14, 361-379		60
222	Bleeding associated with the management of acute coronary syndromes. 2017 , 103, 546-562		5
221	Choosing between Enoxaparin and Fondaparinux for the management of patients with acute coronary syndrome: A systematic review and meta-analysis. 2017 , 17, 116		4
220	Adjunctive use of anticoagulants at the time of percutaneous coronary intervention in patients with an acute coronary syndrome treated with fondaparinux: a multinational retrospective review. 2017 , 3, 214-220		0
219	Gender differences in the effects of cardiovascular drugs. 2017 , 3, 163-182		126
218	Management of antithrombotic agents in patients undergoing flexible bronchoscopy. 2017 , 26,		16
217	Anticoagulants in STEMI Interventions. 2017 , 65-74		
216	Guía ESC 2017 sobre el tratamiento del infarto agudo de miocardio en pacientes con elevación del segmento ST. 2017 , 70, 1082.e1-1082.e61		35
215	The role of oral anticoagulant therapy in patients with acute coronary syndrome. 2017 , 8, 353-366		13

214	Antithrombotic Therapy for ACS in Elderly Patients. 2017 , 31, 609-618		1
213	"Mind the gap" acute coronary syndrome in women: A contemporary review of current clinical evidence. 2017 , 227, 840-849		12
212	Acute myocardial infarction. 2017 , 389, 197-210		486
211	Percutaneous Treatment of Cardiovascular Diseases in Women. 2017 ,		
210	Clinical pathways and management of antithrombotic therapy in patients with acute coronary syndrome (ACS): a Consensus Document from the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Cardiology (SIC), Italian Society of Emergency Medicine (SIMEU) and Italian Society of Interventional Cardiology (SICI-GISE). 2017 , 19, D130-D150		3
209	Safety, efficiency and cost effectiveness of Bivalirudin: A systematic review. <i>World Journal of Cardiology</i> , 2017 , 9, 761-772	2.1	2
208	Acute Coronary Syndromes. 2018 , 197-216		0
207	Parenteral Anticoagulants: Direct Thrombin Inhibitors and Pentasaccharides. 2018 , 59-85		
206	Optimal pharmacological therapy in ST-elevation myocardial infarction-a review : A review of antithrombotic therapies in STEMI. 2018 , 26, 296-310		10
205	Trombosis y anticoagulación en la mujer. 2018 , 25, 132-138		
204	Excessive Daytime Sleepiness Independently Predicts Increased Cardiovascular Risk After Myocardial Infarction. 2018 , 7,		31
203	Anticoagulation in Acute Coronary Syndrome-State of the Art. 2018 , 60, 508-513		12
202	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2018 , 39, 119-177	9.5	4237
201	Morphine, Oxygen, Nitrates, and Mortality Reducing Pharmacological Treatment for Acute Coronary Syndrome: An Evidence-based Review. 2018 , 10, e2114		6
200	OBSOLETE: STEMI: Management. 2018 ,		
199	Acute ST-Segment Elevation Myocardial Infarction (STEMI). 2018 , 107-119		
198	Acute Myocardial Infarction: STEMI and NSTEMI. 2018 , 123-146		0
197	Anticoagulant Therapy for Acute Coronary Syndromes. <i>Interventional Cardiology Review</i> , 2018 , 13, 87-92.2		6

196	An update on the use of anticoagulant therapy in ST-segment elevation myocardial infarction. 2018 , 19, 1441-1450	3
195	[Acute coronary syndrome]. 2018 , 160, 52-61	1
194	Partial factorial trials: comparing methods for statistical analysis and economic evaluation. 2018 , 19, 442	1
193	Semisynthesis of ent-norstrobane diterpenoids as potential inhibitor for factor Xa. 2018 , 28, 3813-3815	3
192	Ischemia and Bleeding on the Horns of a Dilemma: Do Only Hard Endpoints Count?. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 137-140	15.1 0
191	Primary Percutaneous Coronary Intervention. 2018 , 417-441	
190	STEMI: Management. 2018 , 474-488	
189	Acute Coronary Syndromes. 2018 , 2142-2151.e2	
188	Prehospital Diagnosis and Management of Acute Myocardial Infarction. 2018 , 15-29	0
187	Varying Effects of Body Mass Index and Mortality in Different Risk Groups. 2018 , 122, 1155-1160	5
186	Primary Angioplasty. 2018 ,	3
185	Stroke After Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention: Incidence, Pathogenesis, and Outcomes. 2019 , 8, e013032	19
184	Are Ticks the Answer to Medical Device-Associated Clotting?. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 2190-2192	15.1 1
183	From Early Pharmacology to Recent Pharmacology Interventions in Acute Coronary Syndromes: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1618-1636	15.1 17
182	Adjuvant antithrombotic therapy in ST-elevation myocardial infarction: A narrative review. 2019 , 38, 289-297	5
181	The blood compatibility challenge. Part 1: Blood-contacting medical devices: The scope of the problem. 2019 , 94, 2-10	66
180	Adjuvant antithrombotic therapy in ST-elevation myocardial infarction: A narrative review. 2019 , 38, 289-297	
179	Systematic Incorporation of Sex-Specific Information Into Clinical Practice Guidelines for the Management of ST -Segment-Elevation Myocardial Infarction: Feasibility and Outcomes. 2019 , 8, e011597	10

178	The clinical use of Fondaparinux: A synthetic heparin pentasaccharide. 2019 , 163, 41-53		19
177	An analysis of randomized controlled trials underpinning ST-elevation myocardial infarction management guidelines. 2019 , 37, 2229-2238		2
176	2019 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Guidelines on the Acute Management of ST-Elevation Myocardial Infarction: Focused Update on Regionalization and Reperfusion. <i>Canadian Journal of Cardiology</i> , 2019 , 35, 107-132	3.8	59
175	Newest Antithrombotic Agents: Uses, Challenges, and Reversal Strategies for Surgical Procedures. 2019 , 481-497		
174	Efficacy of postprocedural anticoagulation after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: A post-hoc analysis of the randomized INNOVATION trial. 2019 , 98, e15277		2
173	Anticoagulation in Acute Coronary Syndrome: Review of Major Therapeutic Advances. 2019 , 26, e184-e197		2
172	Reperfusion Therapies for Acute ST Elevation Myocardial Infarction. 2019 , 103-116.e5		
171	Adjunctive Pharmacologic Therapies in Acute Myocardial Infarction. 2019 , 117-138.e7		1
170	Anticoagulation. 2019 , 368-378.e2		1
169	Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASS-CABG Study. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 121-130	15.1	46
168	Early anticoagulation in the current management of NSTEMI-ACS: Evidence, guidelines, practice and perspectives. 2019 , 275, 39-45		6
167	ST-Elevation Myocardial Infarction. <i>Contemporary Cardiology</i> , 2019 , 261-271	0.1	
166	Bivalirudin during percutaneous coronary intervention in acute coronary syndromes. 2019 , 20, 295-304		6
165	In-hospital outcomes of STEMI patients on warfarin undergoing primary PCI. 2019 , 93, 41-47		1
164	Adjunctive antithrombotic therapy with primary percutaneous coronary intervention in ST elevation myocardial infarction: ATOLL in perspective. <i>European Heart Journal</i> , 2019 , 40, e4-e7	9.5	3
163	Modern Management of ST-Segment Elevation Myocardial Infarction. 2020 , 45, 100393		12
162	Influence of Clinical Trials of Acute Coronary Syndrome Beyond the Primary Hypothesis: A Systematic Review. 2020 , 5, 1286-1297		
161	Large intracoronary thrombus and its management during primary PCI. 2020 , 72, 508-516		1

- 160 Targeting Biological Polyanions in Blood: Strategies toward the Design of Therapeutics. **2020**, 21, 2595-2621 1
- 159 Rationale and design of the RIGHT trial: A multicenter, randomized, double-blind, placebo-controlled trial of anticoagulation prolongation versus no anticoagulation after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. **2020**, 227, 19-30 2
- 158 Female sex impact on culprit plaque at optical coherence tomography analysis in the setting of acute coronary syndrome in OCT-FORMIDABLE registry. **2020**, 16, 123-131 1
- 157 Treatment of thrombosis. **2020**, 105-144
- 156 Pre-hospital management of patients with chest pain and/or dyspnoea of cardiac origin. A position paper of the Acute Cardiovascular Care Association (ACCA) of the ESC. **2020**, 9, 59-81 31
- 155 Cardiovascular Medications. **2021**, 597-642 1
- 154 Neurological complications of cardiovascular drugs. **2021**, 177, 319-344 1
- 153 Drugs in Myocardial Infarction. **2021**, 115-124
- 152 Antithrombotic treatment in primary percutaneous coronary intervention. **2021**, 19, 313-324 0
- 151 Antithrombotic strategies in elderly patients with acute coronary syndrome. **2021**, 114, 232-245 1
- 150 Antithrombotic therapy in the elderly and senile age: the consensus opinion of experts of the Russian Association of Gerontologists and Geriatricians and the National Society of Preventive Cardiology. **2021**, 20, 2847 1
- 149 Myocardial Infarction with and without ST-segment Elevation: a Contemporary Reappraisal of Similarities and Differences. **2021**, 17, e230421189013 2
- 148 Anticoagulation in ST-Elevation Myocardial Infarction. **2021**, 10, 307-316 0
- 147 Contemporary use of anticoagulation in the cardiac catheterization laboratory: a review. **2021**,
- 146 Infarto agudo de miocardio. SCACEST. **2021**, 13, 2177-2184
- 145 Fondaparinux During Intra-Aortic Balloon Pump Counterpulsation in Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention. **2021**, 30, 1545-1551
- 144 Anticoagulants and Primary PCI. **2018**, 109-118 1
- 143 ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/NonST-Segment Elevation Myocardial Infarction Summary Article. **2011**, 385-404 2

142	Unstable Angina and NonST Elevation Myocardial Infarction. 2012 , 1178-1209		5
141	Percutaneous Coronary Intervention. 2012 , 1270-1300		3
140	STEMI and NSTEMI: Real-world Study in Mexico (RENASCA). 2018 , 49, 609-619		12
139	Anticoagulant activity and pleiotropic effects of heparin. 2020 , 45, 147-157		3
138	Una historia resumida. Impacto de los avances en cardiopatía isquémica. 2017 , 17, 2-6		1
137	Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey. <i>European Heart Journal</i> , 2021 , 42, 339-351	9.5	24
136	Acute Coronary Syndromes. 2009 , 535-596		9
135	Current Antithrombotic Therapy in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Interventions. <i>Interventional Cardiology Review</i> , 2014 , 9, 94-101	4.2	2
134	2020 Clinical practice guidelines for Acute ST-segment elevation myocardial infarction. 2020 , 25, 4103		59
133	Fondaparinux in the management of patients with ST-elevation acute myocardial infarction. <i>Vascular Health and Risk Management</i> , 2006 , 2, 371-8	4.4	2
132	Emerging Anticoagulants and Heparin-Induced Thrombocytopenia: Indirect and Direct Factor Xa Inhibitors and Oral Thrombin Inhibitors. 2007 , 441-462		5
131	EURASIAN CLINICAL GUIDELINES ON DIAGNOSIS AND TREATMENT OF ACUTE CORONARY SYNDROME WITH ST SEGMENT ELEVATION (STEMI). 2020 , 4-77		9
130	Evaluation of the physical-mechanical properties of cement-lime based masonry mortars produced with mixed recycled aggregates. 2020 , 70, 210		7
129	Acute ST-segment myocardial infarction Evolution of treatment strategies. 2013 , 03, 551-560		2
128	2014 ESC/EACTS guidelines on myocardial revascularization. 2015 , 10, 1024-94		195
127	Prognostic impact of body mass index on in-hospital bleeding complications after ST-segment elevation myocardial infarction. <i>World Journal of Cardiology</i> , 2020 , 12, 44-54	2.1	2
126	Percutaneous treatment in acute coronary syndromes. <i>World Journal of Cardiology</i> , 2011 , 3, 315-21	2.1	2
125	Potential Influential Factors of In-Hospital Myocardial Reinfarction in ST-Segment Elevation Myocardial Infarction (STEMI) Patients: Finding from the Improving Care for Cardiovascular Disease in China- (CCC-) Acute Coronary Syndrome (ACS) Project. 2021 , 2021, 9977312		0

- 124 Facilitated percutaneous coronary intervention. **2006**, 48, 267-271 1
- 123 Hemostatic Aspects of Cardiovascular Medicine. **2007**, 339-369
- 122 Enoxaparin versus Unfractionated Heparin with Fibrinolysis for ST-Elevation Myocardial Infarction. **2007**, 2007, 321-323
- 121 ST-Elevation Myocardial Infarction. **2007**, 246-289
- 120 Anti-thrombin therapy. **2008**, 45-53
- 119 Medicamenteuze preventie en behandeling van atherotrombose. **2008**, 89-101
- 118 Controversies and future approaches. **2008**, 69-76
- 117 Traitement de l'infarctus du myocarde avec sus-décalage du segment ST. **2008**, 127-155
- 116 22 Instabiele angina pectoris en myocardinfarct zonder ST-elevatie op het ECG. **2008**, 193-196
- 115 The Future of Reperfusion Therapy. **2008**, 316-332
- 114 Treatment Opportunities with Fibrinolytic Therapy. **2008**, 71-90
- 113 Anti-thrombin therapy. **2009**, 49-59
- 112 Controversies and future approaches. **2009**, 79-88
- 111 Bias in AJHP supplements. **2008**, 65, 2329-2330
- 110 Which Therapy for Which Condition?. **2009**, 388-458
- 109 CORONARY ARTERY DISEASE. **2009**, 321-365
- 108 Acute cardiac syndromes, investigations and interventions. **2009**, 155-177
- 107 Lysetherapie. **2009**, 307-321

106 Antithrombotic Agents: Platelet Inhibitors, Anticoagulants, and Fibrinolytics. **2009**, 293-340

105 Overview of New Anticoagulant Drugs. **2009**, 133-154

104 Oral Direct Factor Xa Inhibitors. **2009**, 307-326

103 Fibrinolysis for Acute Myocardial Infarction. **2009**, 651-666

102 New Heparins: Synthetic Pentasaccharides. **2009**, 253-268

101 Anticoagulation in Acute Coronary Syndromes. **2009**, 171-196

100 Heparin-Induced Thrombocytopenia. **2010**, 435-447

99 Synthetic Factor Xa Inhibition in Acute Coronary Syndromes. **2010**, 203-215

98 Antithrombin Therapy for Acute ST-Segment Elevation Myocardial Infarction. **2010**, 235-246

97 Antithrombotic Therapy in Percutaneous Coronary Intervention. **2010**, 261-282

96 Fibrinolysis and Facilitated PCI. **2010**, 247-257

95 Medical Management of Acute Coronary Syndromes. **2010**, 867-882

94 Anticoagulant Therapy. **2010**, 126-129

93 Antithrombotic Agents. **2010**, 541-555

92 Coronary Artery Disease. **2010**, 23-95

91 La prévention thrombo-embolique en chirurgie orthopédique et traumatologique majeure. **2010**, 269-278

90 Anticoagulation Therapy. **2010**, 94-102

89 Bleeding Complications in Patients Undergoing Percutaneous Coronary Intervention. **2010**, 240-249

88 Cardiology. 185-193

87 Adjunctive Pharmacologic Therapies. **2010**, 54-64

86 Pharmacology in the Cardiac Catheterization Laboratory. 428-447

85 ST Elevation Myocardial Infarction. **2011**, 227-241

84 Acute Coronary Syndromes and Myocardial Infarction. 234-255

83 Pharmakotherapie. **2011**, 105-141

82 Percutaneous coronary intervention. **2011**, 434-443

81 Management of ST-elevation myocardial infarction. **2011**, 474-484

80 Anticoagulants. **2011**, 232-252

79 Intravenous heparin, low-molecular-weight heparins, and thrombin antagonists. **2011**, 297-306

78 Fibrinolytic therapy. **2011**, 289-297

77 Acute Coronary Syndromes. **2011**, 548-558

76 Acute coronary syndromes. **2011**, 459-467

75 Heparin, LMWH, GIIb/IIIa, and Direct Thrombin Inhibitors. 110-143

74 Hemorrhagic Complications of Anticoagulants in Hospitalized Patients. 291-330

73 Coronary Plaque Rupture in Patients with Acute. **2011**, 49-67

72 Thrombolytic Intervention. **2012**, 142-158

71 Diabetes. **2012**, 30-49

70	Hemostasis, Thrombosis, Fibrinolysis, and Cardiovascular Disease. 2012 , 1844-1867		
69	Percutaneous Coronary Intervention in Acute ST Segment Elevation Myocardial Infarction. 2012 , 237-262		
68	Antithrombotic therapies. 2012 , 44-66		
67	Vitamin K Antagonists. 166-179		
66	Acute coronary syndromes. 2012 , 34-57		
65	Antithrombotic Therapy in ST-Segment Elevation Myocardial Infarction. 205-212		
64	Thrombolytic Therapy and Concomitant Antithrombotic Therapies. 189-204		
63	Anticoagulation Therapy. Heparins, Factor II and Factor Xa Inhibitors. 2014 , 59-122		
62	American Versus European Guidelines: Critical Appraisal. 2014 , 139-184		
61	Adjunctive Pharmacology for Coronary Intervention. 2014 , 143-156		
60	Acute Coronary Syndromes. 2014 , 15-36		1
59	Interventional Management of Acute Myocardial Infarction. 2014 , 207-220		
58	Antithrombotic Issues in Women. 2014 , 321-357		
57	Thrombosis in Diabetes and Its Clinical Management. 185-214		
56	Myocardial Infarction. <i>Contemporary Cardiology</i> , 2015 , 311-367		0.1
55	Hallmark Clinical Trials. <i>Contemporary Cardiology</i> , 2015 , 675-727		0.1
54	Unmet Needs in Anticoagulant Therapy: Potential Role of Rivaroxaban. <i>Cardiology Research</i> , 2015 , 6, 267-277	1.8	0
53	Managing the Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients on Oral Anticoagulation. <i>Interventional Cardiology Review</i> , 2015 , 10, 139-141	4.2	

52	Acute Coronary Syndromes. 2015 , 163-171		
51	Anticoagulation as Adjunctive Treatment and One-Hour Alteplase Infusion. 2015 , 131-149		
50	Peri- and Post-procedural Antithrombotic Therapy in Women. 2017 , 73-100		0
49	Traitement de l'infarctus du myocarde avec sus-décalage du segment ST. 2018 , 99-122.e3		
48	Management of Intracoronary Thrombus. 2018 , 119-135		1
47	Inferior Wall Myocardial Infarction, Acute Coronary Syndrome, Double-vessel Diseases, Chronic Venous Thrombosis, and Type II Diabetes Mellitus. <i>Pondicherry Journal of Nursing</i> , 2020 , 13, 64-65	0.1	
46	Strategia di gestione delle sindromi coronariche acute. <i>EMC - Urgenze</i> , 2020 , 24, 1-13	0	
45	Pharmacoepidemiology for nephrologists (part 1): concept, applications and considerations for study design. <i>CKJ: Clinical Kidney Journal</i> , 2021 , 14, 1307-1316	4.5	2
44	Acute Coronary Syndrome and Myocardial Infarction. 2020 , 131-140		
43	Causes of gastrointestinal bleeding in oral anticoagulant users compared to non-users in a population-based study. <i>Scandinavian Journal of Gastroenterology</i> , 2021 , 1-7	2.4	0
42	Heparin-Induced Thrombocytopenia. 2008 , 205-238		
41	Management of Acute Myocardial Infarction. 2007 , 183-210		
40	Antiplatelet Agents, Anticoagulants, and Specific Thrombin Inhibitors. 2007 , 331-348		
39	Hallmark Clinical Trials. 2007 , 381-394		
38	Prothrombotic markers and early spontaneous recanalization in ST-segment elevation myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2007 , 98, 420-6	7	14
37	Management of acute coronary syndromes with fondaparinux. <i>Vascular Health and Risk Management</i> , 2007 , 3, 321-9	4.4	10
36	Contemporary therapy of acute ST-elevation myocardial infarction. <i>Texas Heart Institute Journal</i> , 2009 , 36, 273-81	0.8	3
35	Reperfusion for STEMI in current Canadian practice: Are we closing the care gap?. <i>McGill Journal of Medicine</i> , 2011 , 13, 6		

34	Myocardial infarction in the elderly. 2011 , 2, 116-37		20
33	Oral direct thrombin inhibition: a double-edged sword?. <i>Heart, Lung and Vessels</i> , 2015 , 7, 191-7		2
32	A novel treatment of refractory coronary embolism: thrombus aspiration catheter-assisted twisting wire technique. <i>Journal of Geriatric Cardiology</i> , 2020 , 17, 110-115	1.7	1
31	Heparin use in acute coronary syndromes and cardiovascular interventions: habit or evidence based?. <i>European Heart Journal</i> , 2022 ,	9.5	0
30	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. <i>Journal of the American College of Cardiology</i> , 2021 ,	15.1	42
29	ST-Segment Elevation Myocardial Infarction. 2022 , 38-73		
28	Fondaparinux: A cornerstone drug in acute coronary syndromes.. <i>World Journal of Cardiology</i> , 2022 , 14, 40-53	2.1	0
27	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i> , 2021 , CIR0000000000001038	16.7	23
26	Anticoagulation After Primary PCI: The Land of Promises and Uncertainty.. <i>JACC: Cardiovascular Interventions</i> , 2022 , 15, 264-267	5	1
25	Periprocedural Antithrombotic Treatment in Complex Percutaneous Coronary Intervention.. <i>Journal of Cardiovascular Pharmacology</i> , 2022 , 79, 407-419	3.1	0
24	Parenteral Anticoagulant Agents in PCI. 2022 , 439-445		
23	Primary and Rescue PCI in STEMI. 2022 , 154-166		
22	Basics of Antiplatelet and Anticoagulant Therapy for Cardiovascular Disease. 2022 , 407-419		
21	Anticoagulants: dose control methods and inhibitors. <i>Obstetrics, Gynecology and Reproduction</i> , 2022 , 16, 158-175	0.5	0
20	Which therapy for which condition?. 2013 , 463-541		
19	Antithrombotic agents: Platelet inhibitors, acute anticoagulants, fibrinolytics, and chronic anticoagulants. 2013 , 332-397		1
18	ADEQUATE ANTITHROMBOTIC THERAPY: REDUCTION OF MORTALITY BY THE RESULTS OF INTERNATIONAL CLINICAL TRIALS (literature review). <i>Problemy Zdorov'ya i Biologii</i> , 2013 , 22-29	0.2	
17	Parenteral anticoagulants in the treatment of acute coronary syndrome: what modern clinical guidelines say. <i>Atherothrombosis</i> , 2022 , 12, 46-58	0.3	

16	Sex-related differences in plasma amino acids of patients with ST-elevation myocardial infarction and glycine as risk marker of acute heart failure with preserved ejection fraction. <i>Amino Acids</i> ,	3.5	
15	The Evolution of Anticoagulation for Percutaneous Coronary Intervention:A 40-Year Journey. <i>Canadian Journal of Cardiology</i> , 2022 ,	3.8	○
14	Choosing Between Enoxaparin and Fondaparinux for the Prevention of Thromboembolism: A Meta-Analysis of Randomized Trials. <i>Egyptian Journal of Critical Care Medicine</i> , 2022 , 9, 22-30	○	
13	Direct thrombin inhibitors and factor Xa inhibitors for acute coronary syndromes: a network meta-analysis. 2022 , 2022,		○
12	Current and Future Insights for Optimizing Antithrombotic Therapy to Reduce the Burden of Cardiovascular Ischemic Events in Patients with Acute Coronary Syndrome. 2022 , 11, 5605		○
11	BLASKI I CIENIE WSPÓZESNEJ FARMAKOTERAPII ANTYKOAGULACYJNEJ. 2016 , 14, 64-72		○
10	Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction [REGION-IM. 2022 , 62, 3-15		○
9	Management of Acute Coronary Syndrome. 2022 , 40, 693-706		○
8	Adjunctive Pharmacologic Agents and Mechanical Devices in Primary Percutaneous Coronary Intervention. 2010 , 39, 230-236		○
7	Management of Acute ST-Elevation Myocardial Infarction: Reperfusion Options. 2010 , 39, 927-933		2
6	Fondaparinux Sodium: Recent Advances in the Management of Thrombosis. 2023 , 28, 107424842211450		○
5	Acute Coronary Syndrome in the Older Adult Populations. 2023 , 303-341		○
4	Gestione delle sindromi coronariche acute nelle prime 48'ore. 2023 , 28, 1-14		○
3	THE ACUTE CORONARY SYNDROME: THE POSSIBILITY OF THE MODERN THERAPY (REFERENCES REVIEW. PART I). 2009 , 12-18		○
2	Clinical Decision Pathway for the Use of Fondaparinux in the Management of Acute Coronary Syndrome (ACS) in Hospitals with and Without Catheter Laboratories: An Expert Opinion from India.		○
1	Tratamiento de los síndromes coronarios agudos en las primeras 48 horas. 2023 , 49, 1-15		○